Avastin gains accelerated approval for breast cancer
Genetech's Avastin (bevacizumab) gains accelerated approval Feb. 22 for first-line treatment of metastatic HER-2 negative breast cancer, in combination with paclitaxel. Based on progression-free survival, the approval follows a mixed vote from the Oncologic Drugs Advisory Committee (1"The Pink Sheet," Dec. 17, 2007, p. 15). Visit 2www.ThePinkSheetDAILY.com for coverage of the late-breaking approval. To sign up for a free trial, visit our website or call 800-332-2181...
You may also be interested in...
While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes
The Honest Company’s new digital and strategy chief joins from Amazon.com where he led development of home security systems and contactless, in-garage delivery for more than 50m Amazon Key customers. More cosmetics people news, including new supply chain and sustainability leadership at the Independent Beauty Association.
Under new user fee agreement, sponsors will get at least 60-day notice when a pre-approval inspection is necessary; regulators and manufacturers hope increased communications will lead to more efficient reviews.